Skip to main content

General Mills (GIS) - Get General Mills, Inc. Report is still a stock to hold for the long term, even as the company missed on earnings due to a slump in cereal sales, according to TheStreet's Jim Cramer. He likes that General Mills bought back stock in the first half of the year, and that the company is taking action like getting rid of the Green Giant label. Cramer said to give the stock some time. 

Cramer was asked by a viewer if Fitbit (FIT) - Get Fitbit, Inc. Class A Report is an acquisition target and he responded that it's not. Cramer also talked about Tesla (TSLA) - Get Tesla Inc Report , which he called a cult stock with a valuation that is suspect. He prefers the 'FANG' stocks over Tesla.  Cramer was asked about Disney (DIS) - Get Walt Disney Company Report now that the long-anticipated Star Wars movie is hitting theatres in hours. He says the stock is not a trade, it's a long-term hold. He also discussed Apple (AAPL) - Get Apple Inc. Report and said he doesn't think sales of the watch are strong. He said he's somewhat concerned about that.

Cramer mentioned Nike (NKE) - Get NIKE, Inc. Class B Report , saying he thinks the company will have a good quarter and good guidance.

A viewer asked what was keeping airline stocks grounded, and Cramer cited competition in the industry, which has caused investors to reassess. He noted that Alaska Air (ALK) - Get Alaska Air Group, Inc. Report doesn't have much competition, so that's one of the better performers. He said he likes Southwest (LUV) - Get Southwest Airlines Co. Report and Delta (DAL) - Get Delta Air Lines, Inc. Report , but he doesn't expect the stocks will do anything until the companies can prove competition is not hurting earnings. 

TheStreet Recommends

Cramer was asked about Honeywell (HON) - Get Honeywell International Inc. Report and 3M (MMM) - Get 3M Company Report and said he likes both of those names. He called Honeywell a buy, and said to start accumulating 3M in the mid-$140s.

In the pharmaceutical sector, he prefers Eli Lilly (LLY) - Get Eli Lilly and Company Report over Merck (MRK) - Get Merck & Co., Inc. Report , citing its balance sheet and strong drug pipeline.

A viewer asked Cramer about MiMedix (MDXG) and Cramer said he's not recommending any of the small biotechs right now. He said the big cap biotechs like Biogen (BIIB) - Get Biogen Inc. Report , Celgene (CELG) - Get Celgene Corporation Report , Amgen (AMGN) - Get Amgen Inc. Report and Gilead (GILD) - Get Gilead Sciences, Inc. Report are so cheap that there's no need to go down to the smaller ones.

Cramer also said he likes stock of CVS (CVS) - Get CVS Health Corporation Report long term, and would not sell it on a Goldman Sachs downgrade. Finally, Cramer said SunEdison (SUNE) is a short squeeze and he's not a fan of the stock because he doesn't like the balance sheet.

Cramer is portfolio manager of Action Alerts PLUS and host of CNBC's "Mad Money." He answers viewer questions from social media in a daily segment with TheStreet TV. You'll find him on Facebook and on Twitter he's @jimcramer, use hashtag CramerQ.